The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2025 to 2030 . Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.
The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.
The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.
This product will be delivered within 1-3 business days.
The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.
The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.
U.S. Biopharmaceutical Third-party Logistics Market Highlights
- The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.
- The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.
- The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the U.S. Biopharmaceutical Third-party Logistics market include:
- UPS Healthcare
- Cardinal Health
- KUEHNE + NAGEL
- AmerisourceBergen Corp.
- McKesson Corporation
- Thermo Fisher Scientific
- DHL International GmbH
- DB Schenker
- Kerry Logistics Network Ltd.
- CEVA Logistics
- Agility Logistics
- SF Express
- XPO Logistics
- Cencora, Inc.
- EVERSANA
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Variables, Trends, & Scope
Chapter 4. U.S. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis
Chapter 5. U.S. Biopharmaceutical Third-Party Logistics Market: Service Estimates & Trend Analysis
Chapter 6. U.S. Biopharmaceutical Third-Party Logistics Market: Product Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- UPS Healthcare
- Cardinal Health
- KUEHNE + NAGEL
- AmerisourceBergen Corp.
- McKesson Corporation
- Thermo Fisher Scientific
- DHL International GmbH
- DB Schenker
- Kerry Logistics Network Ltd.
- CEVA Logistics
- Agility Logistics
- SF Express
- XPO Logistics
- Cencora, Inc.
- EVERSANA
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 56.73 Billion |
| Forecasted Market Value ( USD | $ 87.44 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 15 |
